Division of Infectious Diseases, Department of Medicine, University of California, San Francisco, San Francisco, California, USA
Division of Infectious Diseases, Department of Medicine, University of California, San Francisco, San Francisco, California, USA
Division of HIV, Infectious Diseases, and Global Medicine at Zuckerberg San Francisco General Hospital, Department of Medicine, University of California, San Francisco, San Francisco, California, USA
Division of Infectious Diseases, Department of Medicine, University of California, San Francisco, San Francisco, California, USA
Division of HIV, Infectious Diseases, and Global Medicine at Zuckerberg San Francisco General Hospital, Department of Medicine, University of California, San Francisco, San Francisco, California, USA
Division of Infectious Diseases, Department of Medicine, University of California, San Francisco, San Francisco, California, USA
Correspondence: D. J. Minter, Division of Infectious Diseases, Department of Medicine, Room S380, 513 Parnassus Ave, Box 0654, San Francisco, CA 94143, USA ([email protected]).
Potential conflicts of interest. D. J. M. reports payment from the Antimicrobial Resistance Leadership Group for participation in a systematic review and travel support from the University of California, San Francisco (UCSF), ID Division to attend IDWeek. H. F. C. reports an institutional grant from the National Institutes of Health/National Institute on Allergy and Infectious Diseases (NIH/NIAID) for the Antibacterial Resistance Leadership Group (UM1AI104681); royalties earned as editor for The Sanford Guide to Antimicrobial Therapy; payment for expert testimony in a patent dispute for Nexus Pharmaceuticals and a product liability case for Eli Lilly; support from Merck for participation in a Data and Safety Monitoring or Advisory Board; and stock in Moderna and Merck (spouse's IRA). S. B. D. reports funding for clinical research studies from Gilead, Pfizer, F2G, Regeneron, Chan Zuckerberg Biohub, and NIAID; personal consulting fees from Genentech and Janssen/J+J; travel support from IDSA to speak at IDWeek; a patent for Mif agonists and antagonist and therapeutic uses (US20100143379A1); roles on the IDSA Antibacterial Resistance Committee, CADPH HAI Advisory Committee, Antibacterial Resistance Leadership Group Innovations Group, Laboratory Center, Mentorship Committee, Gram Positive Committee, and Immunosuppressed Host Group; and compensation for clinical events committee participation from Shinogi, Basilea, and Duke Clinical Research Institute. A. A. reports no potential conflicts. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.
Received April 05, 2023
Revised November 10, 2023
This article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model (https://academic.oup.com/pages/standard-publication-reuse-rights)
